Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice

Molecular Therapy

Volumn 19, Issue 11, 2011, Pages 2072-2083

  Eliopoulos, Nicoletta ^a,b,c   Zhao, Jing ^c   Forner, Kathy ^c   Birman, Elena ^c   Young, Yoon Kow ^c   Bouchentouf, Manaf ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; CASPASE 3; CASPASE 7; CISPLATIN; CREATININE; ERYTHROPOIETIN; NITROGEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; UREA;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ERYTHROPOIETIN GENE; GENE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; RENAL PROTECTION; STROMA CELL; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

MUS;

EID: 80455164628     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.162     Document Type: Article

References (48)

1. Brooke, G, Cook, M, Blair, C, Han, R, Heazlewood, C, Jones, B et al. (2007). Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 18: 846-858. (Pubitemid 350138458)
2. Prockop, DJ (2009). Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17: 939-946.
3. Sagrinati, C, Ronconi, E, Lazzeri, E, Lasagni, L and Romagnani, P (2008). Stem-cell approaches for kidney repair: choosing the right cells. Trends Mol Med 14: 277-285.
4. Uccelli, A, Moretta, L and Pistoia, V (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
5. Bi, B, Schmitt, R, Israilova, M, Nishio, H and Cantley, LG (2007). Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 18: 2486-2496. (Pubitemid 47378865)
6. Crisostomo, PR, Markel, TA, Wang, Y and Meldrum, DR (2008). Surgically relevant aspects of stem cell paracrine effects. Surgery 143: 577-581.
7. Imberti, B, Morigi, M, Tomasoni, S, Rota, C, Corna, D, Longaretti, L et al. (2007). Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 18: 2921-2928. (Pubitemid 350058399)
8. Kale, S, Karihaloo, A, Clark, PR, Kashgarian, M, Krause, DS and Cantley, LG (2003). Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 112: 42-49. (Pubitemid 38056374)
9. Pittenger, MF, Mackay, AM, Beck, SC, Jaiswal, RK, Douglas, R, Mosca, JD et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147. (Pubitemid 29282067)
10. Tögel, F, Hu, Z, Weiss, K, Isaac, J, Lange, C and Westenfelder, C (2005). Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 289: F31-F42. (Pubitemid 40863570)
11. Tögel, F, Weiss, K, Yang, Y, Hu, Z, Zhang, P and Westenfelder, C (2007). Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 292: F1626-F1635. (Pubitemid 46701891)
12. Herrera, MB, Bussolati, B, Bruno, S, Fonsato, V, Romanazzi, GM and Camussi, G (2004). Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 14: 1035-1041.
13. Morigi, M, Imberti, B, Zoja, C, Corna, D, Tomasoni, S, Abbate, M et al. (2004). Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 15: 1794-1804. (Pubitemid 38822058)
14. Maiese, K, Li, F and Chong, ZZ (2005). New avenues of exploration for erythropoietin. JAMA 293: 90-95. (Pubitemid 40066704)
15. Weiss, MJ (2003). New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist 8 Suppl 3: 18-29. (Pubitemid 37523379)
16. Westenfelder, C (2002). Unexpected renal actions of erythropoietin. Exp Nephrol 10: 294-298. (Pubitemid 36151243)
17. Bagnis, C, Beaufls, H, Jacquiaud, C, Adabra, Y, Jouanneau, C, Le Nahour, G et al. (2001). Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 16: 932-938. (Pubitemid 32440364)
18. Bahlmann, FH and Fliser, D (2009). Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 18: 15-20.
19. Fliser, D and Haller, H (2007). Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol 44: 212-217. (Pubitemid 47031230)
20. Johnson, DW, Pat, B, Vesey, DA, Guan, Z, Endre, Z and Gobe, GC (2006). Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69: 1806-1813. (Pubitemid 43739209)
21. Vaziri, ND, Zhou, XJ and Liao, SY (1994). Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266(3 Pt 2): F360-F366.
22. Bartholomew, A, Patil, S, Mackay, A, Nelson, M, Buyaner, D, Hardy, W et al. (2001). Baboon mesenchymal stem cells can be genetically modifed to secrete human erythropoietin in vivo. Hum Gene Ther 12: 1527-1541. (Pubitemid 34248288)
23. Daga, A, Muraglia, A, Quarto, R, Cancedda, R and Corte, G (2002). Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice. Gene Ther 9: 915-921. (Pubitemid 34812281)
24. Eliopoulos, N, Al-Khaldi, A, Crosato, M, Lachapelle, K and Galipeau, J (2003). A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 10: 478-489. (Pubitemid 36395265)
25. Eliopoulos, N, Gagnon, RF, Francois, M and Galipeau, J (2006). Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 17: 1576-1584. (Pubitemid 43794660)
26. Eliopoulos, N, Lejeune, L, Martineau, D and Galipeau, J (2004). Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modifed marrow stromal cells. Mol Ther 10: 741-748. (Pubitemid 39272863)
27. Chen, CP, Lee, YJ, Chiu, ST, Shyu, WC, Lee, MY, Huang, SP et al. (2006). The application of stem cells in the treatment of ischemic diseases. Histol Histopathol 21: 1209-1216. (Pubitemid 44614503)
28. Herrera, MB, Bussolati, B, Bruno, S, Morando, L, Mauriello-Romanazzi, G, Sanavio, F et al. (2007). Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72: 430-441. (Pubitemid 47237610)
29. Bussolati, B, Hauser, PV, Carvalhosa, R and Camussi, G (2009). Contribution of stem cells to kidney repair. Curr Stem Cell Res Ther 4: 2-8.
30. Bahlmann, FH, de Groot, K, Haller, H and Fliser, D (2004). Erythropoietin: is it more than correcting anaemia? Nephrol Dial Transplant 19: 20-22. (Pubitemid 38072608)
31. Kuwana, H, Terada, Y, Kobayashi, T, Okado, T, Penninger, JM, Irie-Sasaki, J et al. (2008). The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int 73: 430-445. (Pubitemid 351186288)
32. Tögel, F, Cohen, A, Zhang, P, Yang, Y, Hu, Z and Westenfelder, C (2009). Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 18: 475-485.
33. Fishbane, S, Ragolia, L, Palaia, T, Johnson, B, Elzein, H and Maesaka, JK (2004). Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 65: 452-458. (Pubitemid 38130639)
34. Sharples, EJ, Patel, N, Brown, P, Stewart, K, Mota-Philipe, H, Sheaff, M et al. (2004). Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124. (Pubitemid 39031350)
35. Eliopoulos, N, Stagg, J, Lejeune, L, Pommey, S and Galipeau, J (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 106: 4057-4065. (Pubitemid 41775910)
36. Arany, I and Safrstein, RL (2003). Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464. (Pubitemid 37176691)
37. Pabla, N and Dong, Z (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007. (Pubitemid 351543900)
38. Heydorn K, Rietz B, Kraruphansen A (1998). Distribution of platinum in patients treated with cisplatin determined by radiochemical neutron activation analysis. J Trace Elem Exp Med 11: 37-43. (Pubitemid 28176852)
39. Kuo, TK, Hung, S P, Chuang, CH, Chen, CT, Shih, YR, Fang, SC et al. (2008). Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134: 2111-2121.
40. Lee, RH, Seo, MJ, Reger, RL, Spees, JL, Pulin, AA, Olson, SD et al. (2006). Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103: 17438-17443. (Pubitemid 44788987)
41. Fry, AC and Farrington, K (2006). Management of acute renal failure. Postgrad Med J 82: 106-116. (Pubitemid 43266139)
42. Golab, F, Kadkhodaee, M, Zahmatkesh, M, Hedayati, M, Arab, H, Schuster, R et al. (2009). Ischemic and non-ischemic acute kidney injury cause hepatic damage. Kidney Int 75: 783-792.
43. Hassoun, HT, Grigoryev, DN, Lie, ML, Liu, M, Cheadle, C, Tuder, RM et al. (2007). Ischemic acute kidney injury induces a distant organ functional and genomic response distinguishable from bilateral nephrectomy. Am J Physiol Renal Physiol 293: F30-F40. (Pubitemid 47344998)
44. Kelly, KJ (2006). Acute renal failure: much more than a kidney disease. Semin Nephrol 26: 105-113. (Pubitemid 43363385)
45. Hagiwara, M, Shen, B, Chao, L and Chao, J (2008). Kallikrein-modifed mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and infammation. Hum Gene Ther 19: 807-819.
46. Gooch A, Doty J, Flores J, Swenson L, Toegel FE, Reiss GR, et al. (2008). Initial report on a phase I clinical trial: Prevention and treatment of post-operative acute kidney injury with allogeneic mesenchymal stem cells in patients who require on-pump cardiac surgery. Cell Ther Transplant 1: 31-35.
47. Meirelles, Lda S and Nardi, NB (2003). Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 123: 702-711. (Pubitemid 37468069)
48. Phinney, DG, Kopen, G, Isaacson, RL and Prockop, DJ (1999). Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem 72: 570-585. (Pubitemid 29088308)